Diagnostic value of microRNA panel in endometrial cancer: A systematic review

Hannah Donkers, Ruud Bekkers and Khadra Galaal _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2020; 11:2010-2023. https://doi.org/10.18632/oncotarget.27601

Metrics: PDF 1668 views  |   Full Text 2781 views  |   ?  


Hannah Donkers1, Ruud Bekkers2,3 and Khadra Galaal1,4

1 Royal Cornwall Hospital NHS Trust, Truro, Cornwall, United Kingdom

2 Grow School for Oncology and Developmental Biology, Maastricht University, The Netherlands

3 Catharina Hospital, Eindhoven, The Netherlands

4 Exeter University, Exeter, United Kingdom

Correspondence to:

Khadra Galaal,email: [email protected], [email protected]

Keywords: diagnostic tests; diagnostic biomarkers; endometrial cancer; MicroRNAs; uterine neoplasms

Received: February 01, 2020     Accepted: April 03, 2020     Published: May 26, 2020


Purpose: We conducted a systematic review to evaluate the overall diagnostic accuracy of miRNAs in detecting endometrial cancer.

Materials and Methods: A systematic search of Medline, Embase, Cinahl and the Cochrane Controlled Register of Trials was performed to identify studies reporting on the diagnostic value of miRNA in EC patients. Included were diagnostic studies looking at miRNA expression in women diagnosed with endometrial cancer. Two reviewers independently selected studies and assessed quality of studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score system. Data extraction was completed and the vote-counting strategy was used to rank miRNAs.

Results: 26 studies were included with a total number of 1,400 EC patients reporting on 106 differentially expressed miRNAs. The most frequently found up-regulated miRNA was miR-205 followed by miR-200c, -223, -182, -183 and -200a. In addition, miR-135b, miR-429, miR-141 and miR-200b were also frequently up-regulated. There was less consensus on down-regulated miRNAs.

Conclusions: miRNAs yield a promising diagnostic biomarker potential in endometrial cancer, especially miR-205, the miR-200 family and miR-135b, -182, -183 and -223. However, no sufficient high quality data are available to draw hard conclusions. More research is needed to validate the diagnostic potential of these miRNAs in larger studies. In addition, the potential of urine as a non-invasive biofluid should be investigated in more detail.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27601